ifosfamide

Summary

Summary: Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.

Top Publications

  1. Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol). 2007;19:108-14 pubmed
    Encephalopathy is a potentially fatal toxicity of ifosfamide. Clinical manifestations of encephalopathy range from fatigue and confusion to coma and death...
  2. Hamberg P, Boers Sonderen M, van der Graaf W, de Bruijn P, Suttle A, Eskens F, et al. Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study. Br J Cancer. 2014;110:888-93 pubmed publisher
    ..and pharmacokinetic (PK)/pharmacodynamics study of pazopanib combined with two different schedules of ifosfamide. In a 3+3+3 design, patients with advanced solid tumours received escalating doses of oral pazopanib combined ..
  3. Ferrari S, Palmerini E, Alberghini M, Staals E, Mercuri M, Barbieri E, et al. Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study. Tumori. 2010;96:213-8 pubmed
    ..To investigate a six-drug combination in patients with nonmetastatic Ewing sarcoma, focusing on chemotherapy-induced necrosis and chemotherapy toxicity in adult and pediatric patients...
  4. Grassin F, Paleiron N, André M, Caliandro R, Bretel J, Terrier P, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. J Thorac Oncol. 2010;5:893-7 pubmed
    ..to evaluate the response rate, progression free survival, overall survival and toxicity of combined etoposide, ifosfamide, and cisplatin in patients with advanced thymoma and thymic carcinoma...
  5. Hockenberry M, Hooke M, Gregurich M, McCarthy K, Sambuco G, Krull K. Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide. Oncol Nurs Forum. 2010;37:E16-27 pubmed publisher
    ..and performance status in children and adolescents before and after receiving cisplatin, doxorubicin, or ifosfamide chemotherapy. A prospective, descriptive, within-group, before-and-after-chemotherapy design was used...
  6. Lin F, Wang Q, Yu W, Tang L, Zheng S, Sun Y, et al. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol. 2011;7:270-5 pubmed publisher
    ..investigate the efficacy and toxic side effects of two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide on treating Chinese osteosarcoma patients...
  7. Boni C, Tiseo M, Boni L, Baldini E, Recchia F, Barone C, et al. Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br J Cancer. 2012;106:658-65 pubmed publisher
    ..of replacing cisplatin (P) with a non-platinum agent, vinorelbine (N), and (2) the role of adding a third agent, ifosfamide (I), in a doublet based on gemcitabine (G)...
  8. Hanly L, Rieder M, Huang S, Vasylyeva T, Shah R, Regueira O, et al. N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide. J Popul Ther Clin Pharmacol. 2013;20:e132-45 pubmed
    Nephrotoxicity is a serious side effect associated with ifosfamide use...
  9. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch D, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184-90 pubmed publisher
    ..in first relapse or who were refractory after first-line therapy were randomly assigned to either rituximab, ifosfamide, etoposide, and carboplatin (R-ICE) or rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP)...

More Information

Publications68

  1. Mir O, Berrada N, Domont J, Cioffi A, Boulet B, Terrier P, et al. Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. Cancer Chemother Pharmacol. 2012;69:357-67 pubmed publisher
    Doxorubicin and ifosfamide are highly active drugs for the treatment of high-grade sarcomas, but little is known on the optimal management of young patients who develop such malignancies during pregnancy...
  2. Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, et al. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant. 2011;46:784-9 pubmed publisher
  3. Gadducci A, Fabrini M, Perrone F, Manfredi B, Fanucchi A, Laliscia C, et al. Pattern of failures and clinical outcome of patients with locally advanced cervical cancer treated with a tailored integrated therapeutic approach. Anticancer Res. 2010;30:3731-5 pubmed
    ..The identification of biological variables able to predict response to NACT is strongly warranted for an accurate selection of patients who may really benefit from chemosurgical treatment. ..
  4. Ohgaki K, Horiuchi K, Mizutani S, Sato M, Kondo Y. Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney that responded to low-dose chemotherapy with ifosfamide, etoposide, and doxorubicin. Int J Clin Oncol. 2010;15:210-4 pubmed publisher
    ..Severe multiple liver metastases occurred 6 months after surgery, and six courses of chemotherapy with ifosfamide, etoposide and doxorubicin were performed...
  5. Hockenberry M, Hooke M, Gregurich M, McCarthy K. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. J Pediatr Hematol Oncol. 2009;31:664-9 pubmed publisher
    ..The purpose of this study was to examine fatigue and carnitine in children/adolescents before and after ifosfamide, cisplatin, or doxorubicin chemotherapy. Sixty-seven patients from 2 children's cancer centers participated...
  6. Kasper B, Scharrenbroich I, Schmitt T, Wuchter P, Dietrich S, Ho A, et al. Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study. Bone Marrow Transplant. 2010;45:1234-8 pubmed publisher
    ..After four courses of chemotherapy consisting of doxorubicin and ifosfamide, responding patients in at least partial response (PR) were treated with high-dose chemotherapy (n=9); all other ..
  7. Daugaard G, Skoneczna I, Aass N, de Wit R, De Santis M, Dumez H, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germina. Ann Oncol. 2011;22:1054-61 pubmed publisher
    To compare the efficacy of one cycle of standard dose cisplatin, etoposide, and ifosfamide (VIP) plus three cycles of high-dose VIP followed by stem-cell infusion [high-dose chemotherapy (HD-CT arm)] to four cycles of standard cisplatin, ..
  8. Saito R, Kumabe T, Sonoda Y, Kanamori M, Yamashita Y, Watanabe M, et al. Combination chemotherapy with ifosfamide, cisplatin, and etoposide for medulloblastoma: single-institute experience and differences in efficacy for subgroups of medulloblastoma. Childs Nerv Syst. 2011;27:1399-406 pubmed publisher
    ..In Japan, ICE chemotherapy consisting of cisplatin, ifosfamide, and etoposide is one of the most common regimens...
  9. Pagliaro L, Williams D, Daliani D, Williams M, Osai W, Kincaid M, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28:3851-7 pubmed publisher
    ..We performed a phase II study of neoadjuvant chemotherapy with the objective of determining the response rate, time to progression (TTP), and overall survival (OS) among patients with bulky adenopathy...
  10. Richards A, Marshall H, McQuary A. Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity. J Oncol Pharm Pract. 2011;17:372-80 pubmed publisher
    A serious adverse effect that can limit the utility of ifosfamide is neurotoxicity, known as ifosfamide-induced encephalopathy (IIE)...
  11. Sleijfer S, Ouali M, van Glabbeke M, Krarup Hansen A, Rodenhuis S, Le Cesne A, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research a. Eur J Cancer. 2010;46:72-83 pubmed publisher
    ..As ifosfamide is frequently applied in first line systemic therapy, we aimed to establish prognostic and predictive factors ..
  12. Afzal S, Wherrett D, Bartels U, Tabori U, Huang A, Stephens D, et al. Challenges in management of patients with intracranial germ cell tumor and diabetes insipidus treated with cisplatin and/or ifosfamide based chemotherapy. J Neurooncol. 2010;97:393-9 pubmed publisher
    ..protocols have used pre-radiation chemotherapy with combinations of etoposide, carboplatin and/or cisplatin, and ifosfamide. Management of DI in these patients requires monitoring of electrolytes and fluids during chemotherapy and ..
  13. Park S, Lee S, Lee J, Park S, Park J, Kang W, et al. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors. Onkologie. 2011;34:416-20 pubmed publisher
    In relapsed germ cell tumors, salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) is a well-established regimen for patients with favorable features such as a primary testicular tumor and prior complete remission (CR) ..
  14. Motomura K, Natsume A, Fujii M, Ito M, Momota H, Wakabayashi T. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. Leuk Lymphoma. 2011;52:2069-75 pubmed publisher
    In the present study, we aimed to evaluate the safety and efficacy of DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy for the treatment of patients with primary central nervous system lymphoma (PCNSL)...
  15. Lashkari A, Chow W, Valdes F, Leong L, Phan V, Twardowski P, et al. Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Res. 2009;29:3281-8 pubmed
    ..The first cycle of HDCT consisted of doxorubicin (150 mg/m(2)) and ifosfamide (14 g/m(2)) mixed with mesna (14 g/m(2)), while the second cycle consisted of melphalan (150 mg/m(2)) and ..
  16. Lee S, Chang M, Baek K, Han B, Lim T, Lee J, et al. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. Oncology. 2011;80:257-61 pubmed publisher
    For patients with refractory bone and soft tissue sarcoma (STS), treatment options have been limited. Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity...
  17. Yamada N, Hata M, Ohyama H, Yamanegi K, Kogoe N, Nakasho K, et al. Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model. Tumour Biol. 2009;30:176-84 pubmed publisher
    ..subcutaneously with highly metastatic murine osteosarcoma cells (LM8) and then underwent chemotherapy with ifosfamide (30 or 60 mg/kg body weight, days 14-16), immunotherapy with IL-18 (2 microg/mouse, days 18-24) or combined ..
  18. Janeway K, Grier H. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010;11:670-8 pubmed publisher
    ..osteosarcoma with active anti-osteosarcoma chemotherapy agents, high-dose methotrexate, doxorubicin, cisplatin, ifosfamide, and etoposide to recognise and understand rare toxicities associated with these agents, and to identify the ..
  19. Elstrom R, Andemariam B, Martin P, Ruan J, Shore T, Coleman M, et al. Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53:1469-73 pubmed publisher
    ..We investigated the addition of bortezomib to rituximab, dexamethasone, ifosfamide, cisplatin and etoposide (VIPER)...
  20. Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, et al. Long-term evaluation of Ifosfamide-related nephrotoxicity in children. J Clin Oncol. 2009;27:5350-5 pubmed publisher
    b>Ifosfamide is widely used in pediatric oncology but its nephrotoxicity may become a significant issue in survivors. This study is aimed at evaluating the incidence of late renal toxicity of ifosfamide and its risk factors...
  21. Bruheim S, Xi Y, Ju J, Fodstad O. Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. Clin Cancer Res. 2009;15:7161-9 pubmed publisher
    ..from a panel of 10 different human osteosarcoma xenografts and related the results to their sensitivity to ifosfamide, doxorubicin, and cisplatin...
  22. Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, et al. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer. 2011;129:680-90 pubmed publisher
  23. Kitamura H, Taguchi K, Kunishima Y, Yanase M, Takahashi A, Shigyo M, et al. Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group. Cancer Sci. 2011;102:1171-5 pubmed publisher
    ..of this phase II study was to evaluate the efficacy and toxicity of the three-drug combination of paclitaxel, ifosfamide, and nedaplatin (TIN)...
  24. Demetri G, Chawla S, von Mehren M, Ritch P, Baker L, Blay J, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27:4188-96 pubmed publisher
    ..liposarcoma or leiomyosarcoma after failure of prior conventional chemotherapy including anthracyclines and ifosfamide. Patients were randomly assigned to one of two trabectedin regimens (via central venous access): 1...
  25. Milowsky M, Nanus D, Maluf F, Mironov S, Shi W, Iasonos A, et al. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol. 2009;27:4062-7 pubmed publisher
    Sequential chemotherapy with doxorubicin and gemcitabine (AG) followed by ifosfamide, paclitaxel, and cisplatin (ITP) was previously demonstrated to be well tolerated in patients with advanced transitional cell carcinoma (TCC)...
  26. Woll P, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra H, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13:1045-54 pubmed publisher
    ..Chemotherapy consisted of five cycles of doxorubicin 75 mg/m(2), ifosfamide 5 g/m(2), and lenograstim every 3 weeks...
  27. Ingemi A, Bota V, Peguero A, Charpentier M. Fanconi's syndrome and nephrogenic diabetes insipidus in an adult treated with ifosfamide. Pharmacotherapy. 2012;32:e12-6 pubmed publisher
    ..b>Ifosfamide-induced Fanconi's syndrome is reported in about 1...
  28. Chawla S, Staddon A, Hendifar A, Messam C, Patwardhan R, Kamel Y. Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. BMC Cancer. 2013;13:121 pubmed publisher
    ..tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy.
  29. Hamberg P, Steeghs N, Loos W, van de Biessen D, den Hollander M, Tascilar M, et al. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. Br J Cancer. 2010;102:1699-706 pubmed publisher
    ..to define the maximally tolerated dose (MTD) of sunitinib combined with two different infusion schedules of ifosfamide. Patients with advanced solid tumours, good performance score, good organ function, and no standard therapy ..
  30. Eckert F, Matuschek C, Mueller A, Weinmann M, Hartmann J, Belka C, et al. Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis. Radiat Oncol. 2010;5:55 pubmed publisher
    ..We analyzed retrospectively 11 cases of radiochemotherapy with single-agent ifosfamide in patients with macroscopic soft-tissue sarcomas...
  31. Issels R, Lindner L, Verweij J, Wust P, Reichardt P, Schem B, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010;11:561-70 pubmed publisher
    ..deep to the fascia) were randomly assigned to receive either neo-adjuvant chemotherapy consisting of etoposide, ifosfamide, and doxorubicin (EIA) alone, or combined with regional hyperthermia (EIA plus regional hyperthermia) in ..
  32. Skinner R, Parry A, Price L, Cole M, Craft A, Pearson A. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose. Pediatr Blood Cancer. 2010;54:983-9 pubmed publisher
    ..cohort study evaluated the natural history of and risk factors for chronic nephrotoxicity 10 years after ifosfamide treatment in childhood...
  33. Dimitrakopoulou Strauss A, Strauss L, Egerer G, Vasamiliette J, Mechtersheimer G, Schmitt T, et al. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med. 2010;51:551-8 pubmed publisher
    ..with nonmetastatic soft-tissue sarcomas, who were treated with neoadjuvant chemotherapy consisting of etoposide, ifosfamide, and doxorubicin...
  34. Kosmas C, Mylonakis N, Tsakonas G, Vorgias G, Karvounis N, Tsavaris N, et al. Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer. Br J Cancer. 2009;101:1059-65 pubmed publisher
    ..Therefore, we evaluated the three-drug combination of paclitaxel-ifosfamide-cisplatin (TIP)...
  35. Turano S, Mastroianni C, Manfredi C, Biamonte R, Ceniti S, Liguori V, et al. Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine. J Neurooncol. 2010;98:131-5 pubmed publisher
    ..Chemotherapy was begun with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine with granulocyte colony-stimulating factor (G-CSF) support after every cycle...
  36. Li F, Patterson A, Höfer C, Krausz K, Gonzalez F, Idle J. Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics. Biochem Pharmacol. 2010;80:1063-74 pubmed publisher
    b>Ifosfamide (IF) and cyclophosphamide (CP) are common chemotherapeutic agents. Interestingly, while the two drugs are isomers, only IF treatment is known to cause nephrotoxicity and neurotoxicity...
  37. Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, et al. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Hematol Oncol. 2013;31:143-50 pubmed publisher
    ..Herein, we report feasibility and activity of a combination of rituximab, ifosfamide and etoposide (R-IE regimen) in a multicentre series of patients with PCNSL relapsed or refractory to high-dose ..
  38. Ferrari S, Ruggieri P, Cefalo G, Tamburini A, Capanna R, Fagioli F, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol. 2012;30:2112-8 pubmed publisher
    ..chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with nonmetastatic osteosarcoma of the extremity...
  39. Giovanis P, Garna A, Marcante M, Nardi K, Giusto M. Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity. Tumori. 2009;95:545-6 pubmed
    Neurotoxicity is a clinically relevant adverse event observed with the use of ifosfamide. It is usually mild, occasionally severe and seldom fatal...
  40. Sayed Ahmed M. L-Carnitine attenuates ifosfamide-induced carnitine deficiency and decreased intramitochondrial CoA-SH in rat kidney tissues. J Nephrol. 2011;24:490-8 pubmed publisher
    The effects of L-carnitine on ifosfamide (IFO)-induced Fanconi syndrome have not been studied to date...
  41. Barnes J, LaCasce A, Feng Y, Toomey C, Neuberg D, Michaelson J, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011;22:1859-64 pubmed publisher
    ..rituximab to CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, and high-dose methotrexate, alternating with ifosfamide, etoposide, and cytarabine) has not been studied despite efficacy in other aggressive CD20-positive NHLs.
  42. Ciarimboli G, Holle S, Vollenbröcker B, Hagos Y, Reuter S, Burckhardt G, et al. New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2. Mol Pharm. 2011;8:270-9 pubmed publisher
    Anticancer treatment with ifosfamide but not with its structural isomer cyclophosphamide is associated with development of renal Fanconi syndrome leading to diminished growth in children and bone problems in adults...
  43. Sayed Ahmed M, Darweesh A, Fatani A. Carnitine deficiency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi Syndrome rat model. Oxid Med Cell Longev. 2010;3:266-74 pubmed publisher
    In addition to hemorrhagic cystitis, Fanconi Syndrome is a serious clinical side effect during ifosfamide (IFO) therapy...
  44. Kiewe P, Thiel E, Reinwald M, Korfel A. Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors. J Neurooncol. 2011;103:629-34 pubmed publisher
    ..Here, we report on the efficacy and toxicity of topotecan/ifosfamide (TOPO/IFO) combination chemotherapy in patients treated for CNS involvement of different solid malignancies...
  45. Joly F, Sevin E, Lortholary A, Priou F, Paitel J, Fabbro M, et al. Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial. Gynecol Oncol. 2010;116:312-6 pubmed publisher
    To evaluate the efficacy of pegylated liposomal doxorubicin (PLD) and continuous infusion ifosfamide (IFO) in ovarian cancer patients who relapse within 1 year after first-line paclitaxel-platinum-based chemotherapy...
  46. Ames B, Lewis L, Chaffee S, Kim J, Morse R. Ifosfamide-induced encephalopathy and movement disorder. Pediatr Blood Cancer. 2010;54:624-6 pubmed publisher
    b>Ifosfamide is a widely used chemotherapeutic agent for the treatment of a broad spectrum of solid tumors...
  47. Farry J, Flombaum C, Latcha S. Long term renal toxicity of ifosfamide in adult patients--5 year data. Eur J Cancer. 2012;48:1326-31 pubmed publisher
    b>Ifosfamide is indicated as first line treatment in a variety of solid tumours in adults. It is known to be nephrotoxic and is often used following therapy with, or as concomitant therapy with other potent nephrotoxins...
  48. Hara I, Miyake H, Yamada Y, Yamanaka K, Furukawa J, Kumano M, et al. Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience. Anticancer Drugs. 2006;17:1057-66 pubmed
    ..We administered 63 courses of high-dose ifosfamide, carboplatin and etoposide chemotherapy (1250 mg/m carboplatin; 1500 mg/m etoposide; 7...
  49. Hertzberg M, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock K. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol. 2006;17 Suppl 4:iv25-30 pubmed
    ..patients with relapsed or refractory lymphoma using an outpatient-based fractionated regimen of ifosfamide, carboplatin and etoposide (ICE) for both salvage and stem cell mobilisation...
  50. Zylberberg B, Dormont D, Madelenat P, Darai E. First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer. Eur J Gynaecol Oncol. 2004;25:327-32 pubmed
    ..p.) paclitaxel and cisplatin and intravenous (i.v.) ifosfamide in untreated patients with Stage IIIc ovarian cancer after cytoreduction or biopsies only...
  51. Pectasides D, Pectasides E, Papaxoinis G, Skondra M, Gerostathou M, Karageorgopoulou S, et al. Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy. J Androl. 2009;30:280-6 pubmed publisher
    Our objective was to investigate the impact of methotrexate, paclitaxel, ifosfamide, and cisplatin (M-TIP) on long-term fertility in poor-risk nonseminomatous germ cell tumors (NSGCT)...
  52. Piura B, Rabinovich A. Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. Eur J Gynaecol Oncol. 2005;26:275-8 pubmed
    To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas...
  53. Nonomura N, Oka D, Nishimura K, Nakayama M, Inoue H, Mizutani Y, et al. Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors. Int J Urol. 2007;14:527-31 pubmed
    The paclitaxel, ifosfamide, and cisplatin regimen has been used to treat metastatic testicular cancer with successful results...
  54. Ferrari S, Pieretti F, Verri E, Tolentinis L, Cesari M, Versari M, et al. Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate. Anticancer Drugs. 2005;16:733-8 pubmed
    ..adult patients who had been submitted to chemotherapy with high-dose methotrexate (MTX), cisplatin and high-dose ifosfamide (IFO). We observed 43 osteosarcoma patients aged 4--34 years (median 16 years)...
  55. Fruscio R, Colombo N, Lissoni A, Garbi A, Fossati R, Ieda N, et al. A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis. Br J Cancer. 2008;98:720-7 pubmed publisher
    To test the feasibility and efficacy of epirubicin and ifosfamide added to first-line chemotherapy with cisplatin and paclitaxel in a phase II randomised clinical trial...
  56. Binotto G, Trentin L, Semenzato G. Ifosfamide and cyclophosphamide: effects on immunosurveillance. Oncology. 2003;65 Suppl 2:17-20 pubmed
    b>Ifosfamide (IF) and cyclophosphamide (CTX) are chemotherapeutic agents frequently used in the treatment of human malignancies...
  57. Kumar S, Chen C, Waxman D, Halpert J. Directed evolution of mammalian cytochrome P450 2B1: mutations outside of the active site enhance the metabolism of several substrates, including the anticancer prodrugs cyclophosphamide and ifosfamide. J Biol Chem. 2005;280:19569-75 pubmed
    ..Finally, the individual mutants were tested for metabolism of the anti-cancer prodrugs cyclophosphamide and ifosfamide. Several of the mutants showed increased metabolism via the therapeutically beneficial 4-hydroxylation pathway, ..
  58. Macdermed D, Miller L, Peabody T, Simon M, Luu H, Haydon R, et al. Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010;76:1147-53 pubmed publisher
    ..All patients received preoperative therapy including ifosfamide (2.5 g/m2 per day for 5 days) with concurrent radiation (28 Gy in 3...
  59. Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs. 2004;15:347-50 pubmed
    This retrospective trial was performed to determine risk factors, incidence and severity of ifosfamide-induced encephalopathy in correlation with patient and treatment characteristics...